Over 10% of cardiology practice patients inappropriately take aspirin
the ONA take:
According to a new study published in the Journal of the American College of Cardiology, researchers from Michael E. DeBakey Veterans Affairs Medical Center in Houston, Texas, have found that more than 10% of patients are inappropriately taking aspirin for primary prevention of cardiovascular disease.
For the study, researchers identified over 254,000 patients who were taking aspirin between 2008 and 2013 from the National Cardiovascular Disease Registry Practice Innovation and Clinical Experience (PINNACLE) registry. The researchers used the Framingham risk calculator to assess the 10-year risk of cardiovascular disease of the 68,808 evaluable patients.
The researchers defined inappropriate aspirin use for primary prevention as taking aspirin when a patient's 10-year risk was less than 6%; some guidelines say inappropriate use is less than a 10% risk. Results showed that 11.6% of patients taking aspirin for primary prevention had a 10-year risk of less than 6%.
In addition, when comparing inappropriate aspirin use among different cardiology practices, researchers found that inappropriate use ranged from 0% to 70% in different practices.
The findings suggest that the 10-year cardiovascular disease risk should be calculated for each patient, and the clinician should discuss the risk versus benefit of aspirin use with that patient.
More than 10% of patients are inappropriately taking aspirin for primary prevention of cardiovascular disease.
- Blood Test Predicts Stem Cell Transplant Success in Myelodysplastic Syndrome
- Immunotherapy and the Future of Prostate Cancer Treatment
- Elderly with NSCLC Can Tolerate Aggressive Radiation Therapy Treatments
- Patients With Urologic Cancer Need Psycho-oncologic Support to Manage High Stress
- E-cigarettes and Replacement Nicotine Therapy Safer Than Tobacco Use
- Lung Cancer Screening Rates Low Among Present and Former Smokers
- Survivors Reporting Chronic Neuropathic Pain Struggle to Retain Jobs
- Timing of Chemotherapy Infusion Affects Inflammatory Response to Chemotherapy
- Postoperative Gemcitabine Plus Capecitabine: A New Standard of Care for Pancreatic Cancer
- Blood-Forming Stem Cell Transplants (Fact Sheet)
- Patients Undergoing Multiple Systemic Therapies for Metastatic Prostate Cancer Expect a Cure
- FDA Grants Priority Review to Ceritinib for First-line Treatment of ALK+ NSCLC
- Overall Health Worse in African American Men Undergoing Active Surveillance For Prostate Cancer
- Clinical Benefit of Simtuzumab Inconsistent for Myelofibrosis
- Follow-up Rates in Active Surveillance for Prostate Cancer Higher in University-Based vs Safety-Net Hospitals
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|